Cancer Management and Research (Jul 2021)

Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art

  • Pitynski K,
  • Mleko M,
  • Pluta E,
  • Czerw A,
  • Sygit K,
  • Karakiewicz B,
  • Banas T

Journal volume & issue
Vol. Volume 13
pp. 5491 – 5508

Abstract

Read online

Michal Mleko,1 Kazimierz Pitynski,1 Elzbieta Pluta,2 Aleksandra Czerw,3,4 Katarzyna Sygit,5 Beata Karakiewicz,6 Tomasz Banas1 1Department of Gynecology and Oncology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Radiotherapy, Maria Sklodowska–Curie Institute - Oncology Centre, Krakow, Poland; 3Department of Health Economics and Medical Law, Medical University of Warsaw, Warsaw, Poland; 4Department of Economic and System Analyses, National Institute of Public Health – NIH, Warsaw, Poland; 5Calisia University, Kalisz, Poland; 6Subdepartment of Social Medicine and Public Health, Department of Social Medicine, Pomeranian Medical University, Szczecin, PolandCorrespondence: Tomasz BanasDepartment of Gynecology and Oncology, Jagiellonian University Medical College, 2nd Jakubowskiego Street, Krakow, PolandTel +48 12 424 8584Fax +48 12 424 8560Email [email protected]: Systemic inflammatory reaction (SIR) is an unfavorable prognostic factor in many malignancies and has a role in all stages of the neoplastic process: initiation, promotion, and disease progression. Analysis of SIR can be performed by assessing indicators (eg, lymphocyte-to-neutrophil, platelet-to-lymphocyte, and monocyte-to-neutrophil ratios) and products of neutrophils and lymphocytes (ie, the systemic immune-inflammation index), or by examining the relationship between levels of C-reactive protein and albumin (based on the Glasgow Prognostic Score, modified Glasgow Prognostic Score, and C-reactive protein-to-albumin ratio). Risk stratification is essential in the clinical management of cancer; hence, the evaluation of these factors has potential applications in the clinical management of patients with cancer and in the development of new therapeutic targets. This review summarizes the current knowledge on SIR indicators and presents their clinical utility in malignancies of the female genital organs.Keywords: breast cancer, cervical cancer, corpus uteri cancers, C-reactive protein, monocyte-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic inflammatory reaction, vulvar cancer, vaginal cancer

Keywords